Amgen highlights 52-week weight loss data for MariTide and cardiovascular outcomes at ADA Scientific Sessions

Amgen announced full results from Part 1 of the Phase II study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase III FOURIER study of Repatha^® (evolocumab) in cardiovascular disease and the VESALIUS-REAL study of real-world lipid management patterns at the 85^th American Diabetes Association (ADA) Scientific Sessions taking place from June 20–23, 2025, in Chicago.

Data for MariTide, an investigational long-acting peptide-antibody conjugate subcutaneously administered monthly or less frequently, will be presented during an expert-led Symposium being held on Monday, June 23 from 1:30 p.m. – 3:00 p.m. CDT. The Symposium will highlight 52-week efficacy, safety and tolerability data from Part 1 of the Phase 2 study, complete data from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study, and additional information on the Phase 3 MARITIME Chronic Weight Management studies. Topline results from Part 1 of the Phase 2 study were announced in November 2024.

“We look forward to sharing results from our cardiometabolic research at the upcoming ADA meeting, which include 52-week data from Part 1 of the Phase 2 MariTide study showing robust weight loss without a weight loss plateau in people living with obesity, with and without Type 2 diabetes,” said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. “These findings have been pivotal in shaping the design of our Phase 3 MARITIME program, and we’re confident these studies will continue to demonstrate the potential of MariTide as a unique and differentiated option for people living with obesity and related conditions.”

Amgen will host a webcast call for the investment community in conjunction with the ADA Scientific Sessions on Monday, June 23 at 4:30 p.m. CDT. Jay Bradner, M.D., executive vice president of Research and Development at Amgen, along with other members of Amgen’s management team, will discuss the MariTide program. The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

At the Scientific Sessions, Amgen will also sponsor the ADA Interactive Obesity Experience. Throughout the meeting, attendees will have the opportunity to contribute to a word cloud project in the Exhibit Hall (Booth #1338) and participate in an immersive video experience in the ADA Member Lounge.

The 85^th Scientific Sessions will not be livestreamed. On-Demand will open on Wednesday, June 25, 2025, following the meeting. Key Amgen posters and presentations include:

Obesity

• Symposium: Once-Monthly MariTide for the Treatment of Obesity in People with or without Type 2 Diabetes: A 52-Week Phase 2 Study
  Session: Monday, June 23 from 1:30 p.m. – 3:00 p.m. CDT, Location: W375 A

Cardiovascular and Repatha

• Cardiovascular Efficacy of Evolocumab in Persons with Type 1 Diabetes Mellitus: Insights from FOURIER Trial
  Abstract #1991, Abstract Session: Sunday, June 22 from 12:30 p.m. – 1:30 p.m. CDT

• Lipid-lowering Therapy Patterns of High-risk Cardiovascular Patients without Prior Myocardial Infarction or Stroke: Vesalius-Real – Results from Patients with High-risk Diabetes in the U.S.
  Abstract #1315, Abstract Session: Saturday, June 21 from 12:30 p.m. – 1:30 p.m. CDT